GCP
INDP icon

GSA Capital Partners’s Indaptus Therapeutics INDP Stock Holding History

GSA Capital Partners’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-297
Closed -$116K – 1596
2021
Q2 		$116K Sell
297
-122
-29% -$53.7K 0.01% 1239
2021
Q1 		$205K Buy
419
+282
+206% +$148K 0.03% 889
2020
Q4 		$53K Buy
137
+40
+41% +$17.5K 0.01% 1134
2020
Q3 		$55K Buy
+97
New +$71.3K 0.01% 1178
2020
Q1 		– Sell
-10
Closed -$11K – 1287
2019
Q4 		$11K Buy
10
+4
+67% +$5.52K ﹤0.01% 1387
2019
Q3 		$10K Buy
+6
New +$17.9K ﹤0.01% 1348

Other funds holding INDP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 23.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GSA Capital Partners's INDP Position: Q3 2021 in Review

GSA Capital Partners sold out of Indaptus Therapeutics (INDP) in Q3 2021, closing a stake of 297 shares — an estimated $116K sold.

GSA Capital Partners first reported a position in INDP in Q3 2019 and held it in 6 quarters. The position peaked at $205K in Q1 2021. 14 funds tracked by Wall St. Rank hold INDP as of Q3 2021.

  • GSA Capital Partners reported no remaining Indaptus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • GSA Capital Partners sold 297 Indaptus Therapeutics shares in Q3 2021, an estimated $116K.
  • GSA Capital Partners first reported a position in Indaptus Therapeutics in Q3 2019 and held it in 6 quarters.
  • GSA Capital Partners's Indaptus Therapeutics position peaked at $205K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.